Weisman A, et al. - In an allopurinol-treated diabetes cohort, researchers evaluated the relationship between allopurinol and mortality and cardiovascular outcomes. Via conducting a population-based retrospective cohort study in Ontario, Canada, they involved eligible patients who were 66+ years old with diabetes and the first prescription for allopurinol between April 1, 2002-March 31, 2012 and were followed until March 31, 2016. Findings suggested an association of allopurinol with reduced mortality and cardiovascular outcomes. Lack of cumulative dose effect and a positive tracer outcome in males, however, suggests residual bias.